TomoTherapy Incorporated announced that the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, Mo., has started treating patients on its second TomoTherapy Hi•Art treatment system. Siteman installed its first Hi•Art system in early 2006. The installation of a second unit enables more cancer patients to benefit from the revolutionary intensity-modulated radiation therapy (IMRT) solution. “We knew the benefits of arc-based radiation delivery before installing our first TomoTherapy unit. Upon installation, we gained the ability to deliver IMRT in a continuous helical pattern, and the infrastructure and workflow to apply image guidance to each treatment, for every patient,” said Dan Low, Ph.D., associate professor of radiation oncology, Washington University School of Medicine. “This is something we cannot do on any other system. As we’ve become more accustomed to the benefits of this platform, we saw a need for a second Hi•Art system.” “As a large clinic with multiple treatment devices, we are able to select the best technology for each patient’s unique needs,” added Imram Zoberi, M.D., assistant professor of radiation oncology at Washington University School of Medicine and medical director of Siteman Cancer Center at Barnes-Jewish West County Hospital in Creve Coeur, Mo. “We use TomoTherapy for a wide variety of cases, and have found it is a particularly suitable solution for advanced breast cancer cases with lymph node involvement. These are difficult cases to treat on conventional machines, because of the need for multiple matching fields. With conventional treatment, substantial amounts of lung, heart (for left-sided cases), and musculoskeletal tissue around the shoulder joint are exposed to significant radiation doses. TomoTherapy allows us to minimize radiation exposure to all of these structures.” Dr. Zoberi continued: “By using TomoTherapy to treat advanced breast cancer cases, we gain a good advantage in plan conformality, critical structure sparing and homogenous dose to the skin surface. We see that patients are tolerating treatment a lot better than with conventional radiation therapy, due to fewer skin issues. We also believe that breast cancer survivors treated with TomoTherapy are less likely to experience limited range of arm motion, which is a common long-term side effect from other forms of radiation. This is an end point in one of our ongoing clinical trials.”